J&J Delivers No Evidence FDA Knew Of "Phantom" Recall - Congressional Staff
This article was originally published in The Tan Sheet
Johnson & Johnson failed to provide proof that FDA acknowledged the firm's plan for a "phantom" recall of a Motrin product, according to Capitol Hill staff
You may also be interested in...
A report by a Johnson & Johnson special committee finds organizational and middle management changes at the firm were the root causes of manufacturing and quality control lapses in the OTC drug business.
A key House committee chairman questions why FDA has not inspected McNeil Consumer Healthcare's Puerto Rico plant despite a requirement that the Johnson & Johnson business pay the agency's costs.
FDA will wield tight oversight of Johnson & Johnson subsidiary McNeil Consumer Healthcare's OTC manufacturing operations under a consent decree filed after the firm's quality-control changes failed to satisfy the agency.